New Genetic Test Identifies Patients At Risk Of Suicide, Makes Antidepressant Drugs Safer
NeuroMark, a Boulder, Colorado company, has announced the immediate availability of a genetic test to identify people at risk of suicidal ideation — thoughts of committing suicide — when prescribed an antidepressant drug. The test, called the Mark-C? test, is expected to help restore public confidence in antidepressant medication and help to reduce a recently announced spike in suicide rates among U.S. youth.
